Scancell Holdings Plc (LON:SCLP)‘s stock had its “buy” rating restated by Panmure Gordon in a research report issued to clients and investors on Monday. They currently have a GBX 68 ($0.89) price target on the stock. Panmure Gordon’s target price would suggest a potential upside of 325.00% from the company’s current price.

Scancell Holdings Plc (LON:SCLP) opened at 16.60 on Monday. Scancell Holdings Plc has a 1-year low of GBX 12.00 and a 1-year high of GBX 25.90. The firm’s market cap is GBX 43.42 million. The stock’s 50 day moving average price is GBX 16.92 and its 200 day moving average price is GBX 17.17.

Scancell Holdings Plc Company Profile

Scancell Holdings plc develops immunotherapies for the treatment of cancer. The Company develops immunotherapies based on its ImmunoBody and Moditope technology platforms. Its ImmunoBody, SCIB1, is being developed for treatment of melanoma and is being evaluated in Phase I/II clinical trial. Its clinical trials demonstrated that SCIB1, when used as monotherapy, has an effect on tumor load, produces a melanoma-specific immune response and survival trend without serious side effects.

Receive News & Ratings for Scancell Holdings Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell Holdings Plc and related companies with's FREE daily email newsletter.